No products in the cart.
Reports & Databases
Subscribe to
our newsletters!
Both drugs contain progestin as well as one other active ingredient and both are used to suppress ovulation. Where is the cheapest amoxicillin syrup price in india Eaubonne misoprostol buy otc and why? This is the second such case that i know of from that area.
That means if you buy something i may make a small commission which helps to keep my blog up and running. It also reduces the risk of infertility and is an aid cytotec fiyati 2022 Racibórz in conception. You can read about the healing process of the human body on the following link:http://www.drweirder.com/article-2.html.
Disclaimer: this website contains affiliate links. Sildenafil is marketed under the http://62ytl.com/06/06/2012/birinci-lig-bank-asya/ brand names cialis (generic name: brand of sildenafil citrate), vardenafil, and tadalafil (generic name: pde5 inhibitor). It is one of the most effective treatments for erectile dysfunction.
Showing 1–20 of 58 results
- May of 2022This report describes and analyzes cadherin 17 (CDH17) as a target opportunity for development of effector-enhanced drug modalities€ 400.00
- May of 2022This report describes and analyzes claudin 6 as a target opportunity for development of effector-enhanced drug modalities€ 500.00
- March of 2022This report provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2021€ 100.00
- March of 2022This report describes and analyzes the field of Targeted Protein Degradation (TPD) from an industry perspective as of March 2022€ 2450.00
- July and October of 2021Package of two reports with emerging evolutionary technologies of Vectorized Antibodies and Prodrug Antibodies & Cytokines€ 2200.00
- October of 2021Landscape description and analysis of prodrug antibodies and cytokines employing conventional and novel masking technologies from an industry perspective as of October 2021€ 2250.00
- July of 2021This report provides you with a landscape description and analysis of direct in vivo delivery of nucleic acid-encoded antibodies employing DNA and mRNA platform technologies from an industry perspective as...€ 2150.00
- March of 2021Compilation of the global sales data of branded originator recombinant therapeutic proteins and antibodies, of selected biosimilars and other novel biologics in the calendar year 2020€ 100.00
- September of 2020This Target Pipeline List provides an overview of inhibitors of the CD47-SIRPα pathway in development as a next generation immuno-oncology treatment of cancer€ 200.00
- August of 2020This report describes the landscape of industry-driven approaches to discover and develop recombinant therapeutic antibodies against SARS-CoV-2 for treatment of COVID-19€ 200.00
- May of 2020This report package includes four reports for the price of two describing and analyzing the landscape of novel technologies to drug the undruggable targets from an industry perspective.€ 4125.00
- May of 2020Report with a landscape analysis of Targeted Protein Degradation (TPD) technologies and of discovery and development of TPD drug candidates from an industry perspective as of May 2020€ 2050.00
- April of 2020This Target Pipeline List provides an overview of STING Agonists or Antagonists in development for treatment of cancer or autoimmune and inflammatory diseases.€ 150.00
- March of 2020Report about COVID-19 Vaccines in Development with landscape analysis of industry-driven R&D projects of vaccines for prevention of COVID-19 as of March 27, 2020€ 100.00
- March of 2020Compilation of the global sales data of branded originator recombinant therapeutic proteins and antibodies and of selected biosimilars in the calendar year 2019€ 90.00
- March of 2020Report about SARS-CoV-2 Treatment & Prevention Approaches undertaken by industry to evaluate existing and discover novel treatments and vaccines for COVID-19.€ 150.00
- February of 2020This report provides an overview of TIGT-targeted immuno-oncology therapeutics in development as monotherapy or in combination with other checkpoint inhibitors.€ 100.00
- March of 2021Online database for annual global sales since 2007 of recombinant therapeutic antibodies & proteins in regulated markets (branded originator products, increasingly also for biosimilars)€ 200.00
- December of 2019Competitive intelligence report about next wave biosimilar antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More as of December 2019€ 600.00
- October of 2019Subscription to this product provides access during one year to all existing reports on stock and all new reports produced by La Merie Publishing during the term of the subscription.€ 4000.00
